HETEROLOGOUS antilymphocyte serum (ALS) is a very potent inhibitor of cell-mediated immune responses such as homograft rejection and delayed hypersensitivity1. It has also been shown to suppress the antibody response to inert antigens such as sheep red blood cells and bacterial products in rodents and other laboratory animals1-3. By contrast, in the several infections of rodents in which the antibody response has been followed, including trichinosis in rats4 and several viral infections of mice5,6, ALS impaired recovery, but the antibody response was not altered. It is therefore of interest that we have found a marked delay in the antibody response associated with delayed recovery from a malaria infection in ALS-treated mice.
ASJC Scopus subject areas